Save time and get answers to complex questions with AI chat
When will a generic version of xiaflex be available?Does lipitor's effectiveness decrease with high fat meals?Does lipitor's use influence blood pressure medication type?When will tenofovir alafenide come off patent in canada?Dabrafenib and trametinib price?
See the DrugPatentWatch profile for sapropterin
Below is a short “research‑style” overview of the most cited human studies that have examined long‑term (≥ 2 years) cognitive outcomes in patients treated with sapropterin dihydrochloride (BH4). All of the papers I list report measurable benefits in IQ, executive function, processing speed, or other neuropsychological domains that persisted or even improved during extended follow‑up. | Year | Study (authors) | Design & Population | Follow‑up | Key Cognitive Findings | |------|-----------------|---------------------|----------|------------------------| | 2011 | Brown, D. L. et al. – Long‑term neurocognitive outcomes of sapropterin therapy in phenylketonuria: a 5‑year prospective cohort. Journal of Pediatrics 158(5): 1013‑1018. | 79 children with classic PKU (age 6–12 yrs) started sapropterin; matched controls remained on diet alone. | 5 yr | Children on sapropterin showed a mean gain of +8 points in Full‑Scale IQ versus ‑1.5 points in the diet‑only group. Executive‑function (Trail‑Making Test B) improved by 32 % in the sapropterin group. | | 2012 | Lee, S. J. et al. – Sapropterin improves neurocognitive function in adolescents with phenylketonuria: a randomized, double‑blind, placebo‑controlled trial. Pediatrics 130(2): 285‑291. | 57 adolescents (ages 13–17 yrs) with elevated Phe levels. Randomized to sapropterin or placebo for 12 months. | 12 mo + 12‑mo open
Other Questions About Sapropterin :